New Clinical Data on AVEO Oncology's Tivozanib and Ficlatuzumab to be Presented at ESMO 2012 Congress
AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on
its lead product candidate tivozanib, partnered with Astellas Pharma
Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab
will be presented at the European Society of Medical Oncology (ESMO)
2012 Congress in Vienna, Austria, September 28 – October 2, 2012.
“At this year's ESMO, investigators will present new data on both our
lead product candidate tivozanib and our HGF inhibitory antibody
ficlatuzumab,” said William Slichenmyer, M.D., Sc.M., chief medical
officer, AVEO Oncology. “We believe the additional TIVO-1 analyses
underscore the safety profile of tivozanib in RCC while the new
ficlatuzumab data demonstrate its targeted inhibition of the HGF ligand.
We look forward to